Paper39998677
CDX2 and SATB2 loss are associated with myeloid cell infiltration and poor survival in colorectal cancer.
Sirniö P and 19 others. Cancer Immunol Immunother, 2025. Cited by 4 papers, by iCite.
Cite this record
ConductScience Library. CDX2 and SATB2 loss are associated with myeloid cell infiltration and poor survival in colorectal cancer. Papers, record 39998677. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39998677
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- CDX2 and SATB2 loss are associated with myeloid cell infiltration and poor survival in colorectal cancer.
- PubMed
Topics14
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Colorectal Neoplasms | Major topic |
| Matrix Attachment Region Binding Proteins | Major topic |
| CDX2 Transcription Factor | Major topic |
| Transcription Factors | Major topic |
| Myeloid Cells | Major topic |
| Humans | |
| Male | |
| Female | |
| Prognosis | |
| Middle Aged | |
| Aged | |
| Tumor Microenvironment | |
| Biomarkers, Tumor | |
| Adult |
Source PubMed
Grants4
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| 59-5619 | Syöpäsäätiö | PubMed | ||
| 220257P | Emil Aaltosen Säätiö | PubMed | ||
| 6021 | Suomen Lääketieteen Säätiö | PubMed | ||
| 230229 | Sigrid Juséliuksen Säätiö | PubMed |
Source PubMed
References45
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 25126956 | The clinical perspectives of CDX2 expression in colorectal cancer: a qualitative systematic review. | Surg Oncol | 2014 | https://conductscience.org/library/papers/25126956 | PubMed |
| 2 | 37002343 | Spatially resolved multimarker evaluation of CD274 (PD-L1)/PDCD1 (PD-1) immune checkpoint expression and macrophage polarisation in colorectal cancer. | Br J Cancer | 2023 | https://conductscience.org/library/papers/37002343 | PubMed |
| 3 | 38369188 | Quantitative Multiplexed Analysis of Indoleamine 2,3-Dioxygenase (IDO) and Arginase-1 (ARG1) Expression and Myeloid Cell Infiltration in Colorectal Cancer. | Mod Pathol | 2024 | https://conductscience.org/library/papers/38369188 | PubMed |
| 4 | 33894556 | Immunohistochemical expression and significance of SATB2 protein in colorectal cancer. | Ann Diagn Pathol | 2021 | https://conductscience.org/library/papers/33894556 | PubMed |
| 5 | 32737450 | Mismatch repair phenotype determines the implications of tumor grade and CDX2 expression in stage II-III colon cancer. | Mod Pathol | 2021 | https://conductscience.org/library/papers/32737450 | PubMed |
| 6 | 31121192 | CDX2 and Muc2 immunohistochemistry as prognostic markers in stage II colon cancer. | Hum Pathol | 2019 | https://conductscience.org/library/papers/31121192 | PubMed |
| 7 | 34582804 | SATB2 preserves colon stem cell identity and mediates ileum-colon conversion via enhancer remodeling. | Cell Stem Cell | 2022 | https://conductscience.org/library/papers/34582804 | PubMed |
| 8 | 22326557 | TNF-α-induced down-regulation of CDX2 suppresses MEP1A expression in colitis. | Biochim Biophys Acta | 2012 | https://conductscience.org/library/papers/22326557 | PubMed |
| 9 | 35449453 | Prognostic significance of spatial and density analysis of T lymphocytes in colorectal cancer. | Br J Cancer | 2022 | https://conductscience.org/library/papers/35449453 | PubMed |
| 10 | 30001238 | Loss of SATB2 Expression in Colorectal Carcinoma Is Associated With DNA Mismatch Repair Protein Deficiency and BRAF Mutation. | Am J Surg Pathol | 2018 | https://conductscience.org/library/papers/30001238 | PubMed |
| 11 | 24713733 | The role of SATB2 as a diagnostic marker for tumors of colorectal origin: Results of a pathology-based clinical prospective study. | Am J Clin Pathol | 2014 | https://conductscience.org/library/papers/24713733 | PubMed |
| 12 | 29675807 | The prognostic impact of CDX2 correlates with the underlying mismatch repair status and BRAF mutational status but not with distant metastasis in colorectal cancer. | Virchows Arch | 2018 | https://conductscience.org/library/papers/29675807 | PubMed |
| 13 | 26789870 | CDX2 as a Prognostic Biomarker in Stage II and Stage III Colon Cancer. | N Engl J Med | 2016 | https://conductscience.org/library/papers/26789870 | PubMed |
| 14 | 29439001 | The Cdx2 homeobox gene suppresses intestinal tumorigenesis through non-cell-autonomous mechanisms. | J Exp Med | 2018 | https://conductscience.org/library/papers/29439001 | PubMed |
| 15 | 25663765 | Loss of CDX2 expression is associated with poor prognosis in colorectal cancer patients. | World J Gastroenterol | 2015 | https://conductscience.org/library/papers/25663765 | PubMed |
| 16 | 31869737 | The local inflammatory response in colorectal cancer - Type, location or density? A systematic review and meta-analysis. | Cancer Treat Rev | 2020 | https://conductscience.org/library/papers/31869737 | PubMed |
| 17 | 36819801 | Diagnostic accuracy of SATB2 in identifying primary and metastatic colorectal carcinoma: a comparative immunohistochemical study. | Ecancermedicalscience | 2022 | https://conductscience.org/library/papers/36819801 | PubMed |
| 18 | 35985421 | The transcription factor Cdx2 regulates inflammasome activity through expression of the NLRP3 suppressor TRIM31 to maintain intestinal homeostasis. | J Biol Chem | 2022 | https://conductscience.org/library/papers/35985421 | PubMed |
| 19 | 37325467 | Potential predictors for CDX2 expression loss and mismatch repair deficiency in colorectal cancer. | Pathol Oncol Res | 2023 | https://conductscience.org/library/papers/37325467 | PubMed |
| 20 | 17008531 | Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. | Science | 2006 | https://conductscience.org/library/papers/17008531 | PubMed |
Cited by1
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 4 citations.
| PMID | Title | Journal | Year | In Papers |
|---|---|---|---|---|
| 42027640 | Role of CDX2 in the prognosis of colorectal cancer across stages 0-IV. | Oncol Lett | 2026 | https://conductscience.org/library/papers/42027640 |
Source PubMed
Genes2
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| CDX2 | 1045 | PubTator's text mining | https://conductscience.org/library/genes/1045 | NCBI Gene |
| SATB2 | 23314 | PubTator's text mining | https://conductscience.org/library/genes/23314 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/39998677
GET https://conductscience.org/api/papers/v1/39998677/references?page=2